Skip to main content
. 2021 Nov 19;4(11):e2135353. doi: 10.1001/jamanetworkopen.2021.35353

Figure 3. Gout Incidence in Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 (DPP4) Inhibitors and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors.

Figure 3.

Gout incidence in the overall study population (A) and the propensity score–matched population (B).